AbbVie (ABBV)
(Delayed Data from NYSE)
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $77.47, marking a +0.43% move from the previous day.
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Congressional Activities on Shutdown in Focus
by Zacks Equity Research
Congressional Activities on Shutdown in Focus
AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
AbbVie (ABBV) misses estimates for both earnings and revenues in fourth quarter. Biosimilar competition impacts Humira sales in ex-U.S. markets. Imbruvica and Mavyret offset Humira decline.
Asia, Congress Activity, Put Futures in the Green
by Mark Vickery
Market indexes are up in today's pre-market ??? the Dow in the green a healthy triple digits ??? despite a disappointing earnings call from Intel and comments from the Commerce Secretary yesterday.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down
by Zacks Equity Research
AbbVie's (ABBV) fourth-quarter 2018 earnings and revenues both missed estimates. The company provided 2019 guidance International Humira sales suffered due to biosimilar competition.
AbbVie (ABBV) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of -1.04% and -0.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q4 sales, genericization of key drugs and weak sales in the EH segment will hurt the same.
Healthcare ETFs in Focus Ahead of Q4 Earnings
by Sweta Killa
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.
The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb
Zacks Investment Ideas feature highlights: International Business Machines, Procter and Gamble, Ford, Intel and Abbvie
by Zacks Equity Research
Zacks Investment Ideas feature highlights: International Business Machines, Procter and Gamble, Ford, Intel and Abbvie
Is a Surprise Coming for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
Blue Chips IBM and Proctor and Gamble Rally on Earnings
by David Borun
Investors are delighted with improved guidance as well as solid earnings
Top Research Reports for Amazon, Verizon & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Verizon (VZ) and AbbVie (ABBV).
5 Amazing Earnings Charts
by Tracey Ryniec
It's not easy to beat nearly every quarter for years but these 5 companies have been doing just that.
J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.